SEVETYS acquired by EURAZEO
Context
Eurazeo acquired a majority stake in Sevetys from Ardian, which had previously financed the group's initial rapid expansion. The transaction included a EUR250 million equity injection from Eurazeo to fuel a new phase of aggressive growth. The investment thesis focuses on consolidating the highly fragmented French veterinary market, which is protected by specific regulatory barriers regarding clinical governance and independence. Sevetys positions itself as a sovereign French alternative to global giants like IVC Evidensia and AniCura. Under Eurazeo's ownership, the group successfully completed approximately 100 acquisitions in 2022 alone, expanding its footprint into new regions such as the Rhone Valley and Grenoble.
SEVETYS, which reported an EBITDA margin of LOGIN in 2022, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.4x).
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Founded in 2017, Sevetys is a leading French veterinary clinic group. It operates a network of over 150 sites across France, including major clusters inIle-de-France, Brittany, and the Loire Valley. The group differentiates itself through a "French model" of governance, ensuring that practicing veterinarians remain significant shareholders and maintain clinical independence while the group centralizes administrative and financial functions.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Similar deals in Healthcare & Pharma
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 07/2022 | LATOUR CAPITAL | PHARMACIE LAFAYETTE - GROUPE HYGIE31 | FRANCE | Health Providers | Latour Capital and Bpifrance acquired a majority stake in Hygie31, the holding company of Pharmacie Lafayette, from Five Arrows (Rothschild & Co). The deal aims to accelerate the group's development in France and Europe through organic growth and an ambitious buy-and-build strategy. |
| 07/2022 | ANDERA PARTNERS | GROUPE RESONANCE IMAGERIE | FRANCE | Health Providers | R�sonance Imagerie, a prominent French medical imaging group, has secured a major financing package from Andera MidCap, Ardian Private Debt, and Five Arrows Debt Partners. Established in 2011, the group currently operates a network of 15 centers across Paris, �le-de-France, and the Centre-Val-de-Loire region, managing 23 high-tech units including MRIs and scanners. |
| 06/2022 | ARDIAN | SIMAGO | FRANCE | Health Providers | Ardian acquired a significant minority stake in Simago. The investment was designed to support the group's rapid "buy-and-build" strategy in a highly fragmented French market. Unlike traditional LBOs, the deal was structured to preserve the medical independence of the associate radiologists, who continue to hold the majority of the capital and voting rights alongside the founding management team. |
| 06/2022 | TRITON PARTNERS | ESPERI CARE | FINLAND | Health Providers | Triton Partners, via its Triton Smaller Mid Cap Fund II, acquired a majority stake in Esperi Care Oy from a consortium of its former creditors, including Danske Bank, SEB, and Ilmarinen, which remain as minority shareholders. The transaction implies a majority control transfer while preserving continuity of public‑sector and employee‑management relationships, with Triton committing to a substantial capital investment to support further service development and operational improvements. The strategic rationale is rooted in Esperi Care’s established position, business model built on recurring and contract‑based care fees, strong regulatory and societal mandate. Triton’s Nordic healthcare expertise, demonstrated through prior investments in Aleris, Ambea, and Mehiläinen, is expected to support the professionalization of care concepts, standardization of operating models, and expansion of service quality without compromising social‑care objectives. |
| 04/2022 | GROUPE BRUXELLES LAMBERT | AFFIDEA | NETHERLANDS | Health Providers | The Brussels Lambert Group (GBL) has finalized the acquisition of a majority stake in Affidea, the European leader in diagnostic imaging and outpatient care, from B-FLEXION (family office), which is exiting the investment after eight years. The transaction is structured as a secondary LBO in which the current management team has reinvested a significant portion of its proceeds alongside GBL to ensure alignment of interests. This buyout marks a major step in the strategic rotation of GBL's portfolio, significantly increasing its exposure to private assets at the expense of its historic listed holdings. |
| 02/2022 | MEINE RADIOLOGIE | ALERIS - RADIOLOGY | SWEDEN | Health Providers | The divestment of Aleris' radiology arm to Meine Radiologie Holding (backed by EQT Infrastructure) marks a significant consolidation in the Nordic diagnostic imaging market. This transaction was executed in tandem with the sale of Aleris' primary care and rehab units to Praktikertjänst, as part of a broader strategic shift. The rationale for Aleris, under Triton's ownership, is to exit non-core segments to focus exclusively on becoming a specialized healthcare provider in Scandinavia. For the acquirer, the deal provides a major entry point into the Norwegian and Swedish markets, significantly expanding its existing German-focused radiology platform. The integration of 36 diagnostic units allows for significant scale advantages in procurement, technological investment, and standardized medical reporting. This move is consistent with the trend of private equity-backed platforms seeking to create pan-European leaders in capital-intensive medical sub-sectors like radiology. |
| 01/2022 | WREN HOUSE | VOYAGE CARE | UNITED KINGDOM | Health Providers | Partners Group and Duke Street agreed to sell 100% of Voyage Care to Wren House Infrastructure Management, following approximately seven years of joint ownership since the 2014 acquisition alongside management. Key value creation initiatives delivered during the holding period include strategic management hires, continued investment in care quality, further development of specialist care disciplines, and capacity expansion through organic development and selective bolt-on acquisitions. |
| 12/2021 | RAMSAY HEALTH CARE | ELYSIUM HEALTHCARE | UNITED KINGDOM | Health Providers | Ramsay Health Care entered into a definitive agreement on December 13, 2021, to acquire 100% of the UK-based mental healthcare provider Elysium Healthcare from BC Partners to solidify its standing within the specialized British clinical landscape. This strategic acquisition was designed to bridge the gap between Ramsay’s existing acute medical hospitals and the specialized psychiatric and complex care segments where demand remains consistently high. By integrating these two distinct healthcare models, the group created a diversified clinical platform capable of managing patients through every stage of their recovery, from secure inpatient wards to community-based residential support. The move was strategically timed to align with broader national shifts toward integrated care models and increased public focus on mental health infrastructure and neurological rehabilitation. |
| 12/2021 | VIVALTO PARTNERS / IK PARTNERS / MACSF / ARKEA CAPITAL / BNP PARIBAS DEVELOPPEMENT | VIVALTO SANTÉ | FRANCE | Health Providers | Vivalto Santé completed its third LBO, with Vivalto Partners — Daniel Caille's newly created investment management vehicle — taking control of the group. IK Partners joined as a key new minority shareholder alongside a broad consortium of reinvesting French institutional investors and the Bpifrance-Mubadala sovereign duo. The transaction is notably characterised by a strong medical and employee shareholder component, with approximately 1,000 physicians and ultimately 35% of employees targeted as co-investors. The financing structure comprises a Term Loan B and a revolving credit facility, supplemented by subordinated instruments arranged by Hayfin. |
| 11/2021 | CERBA HEALTHCARE | LABEXA | FRANCE | Health Providers | Cerba HealthCare acquired Labexa following a competitive auction process managed by Oddo BHF, beating out its main rival Biogroup. The acquisition allows Cerba to significantly strengthen its footprint in the French "Nouvelle-Aquitaine" region. The transaction followed Cerba's massive EUR1.2 billion acquisition of Lifebrain in Italy and was finalized shortly after Cerba's own LBO with EQT. The target's biologist-partners opted for an industrial exit to join a major laboratory network. |
REFERENCES
Valuation range: EV 500M - 1.5b EUR
Revenue range: 100M - 200M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of SEVETYS by EURAZEO are reserved for mynth community members. Register for free to unlock full data.
Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).
Press release: view release
Acquirer: eurazeo